On Tuesday, Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) was 27.69% up from the session before settling in for the closing price of $5.02. A 52-week range for AMLX has been $1.62 – $7.27.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -78.71% over the past five years. When this article was written, the company’s average yearly earnings per share was at 59.46%. With a float of $65.31 million, this company’s outstanding shares have now reached $89.08 million.
Let’s look at the performance matrix of the company that is accounted for 123 employees. In terms of profitability, gross margin is 775.71%, operating margin of 16317.06%, and the pretax margin is 17255.66%.
Amylyx Pharmaceuticals Inc (AMLX) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Amylyx Pharmaceuticals Inc stocks. The insider ownership of Amylyx Pharmaceuticals Inc is 26.74%, while institutional ownership is 76.23%. The most recent insider transaction that took place on Mar 31 ’25, was worth 37,806. In this transaction Chief Financial Officer of this company sold 10,896 shares at a rate of $3.47, taking the stock ownership to the 290,988 shares. Before that another transaction happened on Mar 31 ’25, when Company’s Chief Medical Officer sold 12,425 for $3.47, making the entire transaction worth $43,082. This insider now owns 194,375 shares in total.
Amylyx Pharmaceuticals Inc (AMLX) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 59.46% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 29.78% during the next five years compared to -78.71% drop over the previous five years of trading.
Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) Trading Performance Indicators
You can see what Amylyx Pharmaceuticals Inc (AMLX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 12.05.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.10, a number that is poised to hit -0.46 in the next quarter and is forecasted to reach -1.45 in one year’s time.
Technical Analysis of Amylyx Pharmaceuticals Inc (AMLX)
Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) saw its 5-day average volume 1.66 million, a positive change from its year-to-date volume of 0.92 million. As of the previous 9 days, the stock’s Stochastic %D was 39.17%.
During the past 100 days, Amylyx Pharmaceuticals Inc’s (AMLX) raw stochastic average was set at 92.93%, which indicates a significant increase from 85.05% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 113.19% in the past 14 days, which was higher than the 87.31% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.97, while its 200-day Moving Average is $4.21. Nevertheless, the first resistance level for the watch stands at $6.97 in the near term. At $7.53, the stock is likely to face the second major resistance level. The third major resistance level sits at $8.36. If the price goes on to break the first support level at $5.58, it is likely to go to the next support level at $4.75. The third support level lies at $4.19 if the price breaches the second support level.
Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) Key Stats
There are 89,141K outstanding shares of the company, which has a market capitalization of 571.40 million. As of now, sales total 87,370 K while income totals -301,740 K. Its latest quarter income was -660 K while its last quarter net income were -37,550 K.
